Literature DB >> 21355092

Ischemic neurons prevent vascular regeneration of neural tissue by secreting semaphorin 3A.

Jean-Sébastien Joyal1, Nicholas Sitaras, François Binet, Jose Carlos Rivera, Andreas Stahl, Karine Zaniolo, Zhuo Shao, Anna Polosa, Tang Zhu, David Hamel, Mikheil Djavari, Dario Kunik, Jean-Claude Honoré, Emilie Picard, Alexandra Zabeida, Daya R Varma, Gilles Hickson, Joseph Mancini, Michael Klagsbrun, Santiago Costantino, Christian Beauséjour, Pierre Lachapelle, Lois E H Smith, Sylvain Chemtob, Przemyslaw Sapieha.   

Abstract

The failure of blood vessels to revascularize ischemic neural tissue represents a significant challenge for vascular biology. Examples include proliferative retinopathies (PRs) such as retinopathy of prematurity and proliferative diabetic retinopathy, which are the leading causes of blindness in children and working-age adults. PRs are characterized by initial microvascular degeneration, followed by a compensatory albeit pathologic hypervascularization mounted by the hypoxic retina attempting to reinstate metabolic equilibrium. Paradoxically, this secondary revascularization fails to grow into the most ischemic regions of the retina. Instead, the new vessels are misdirected toward the vitreous, suggesting that vasorepulsive forces operate in the avascular hypoxic retina. In the present study, we demonstrate that the neuronal guidance cue semaphorin 3A (Sema3A) is secreted by hypoxic neurons in the avascular retina in response to the proinflammatory cytokine IL-1β. Sema3A contributes to vascular decay and later forms a chemical barrier that repels neo-vessels toward the vitreous. Conversely, silencing Sema3A expression enhances normal vascular regeneration within the ischemic retina, thereby diminishing aberrant neovascularization and preserving neuroretinal function. Overcoming the chemical barrier (Sema3A) released by ischemic neurons accelerates the vascular regeneration of neural tissues, which restores metabolic supply and improves retinal function. Our findings may be applicable to other neurovascular ischemic conditions such as stroke.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21355092      PMCID: PMC3112046          DOI: 10.1182/blood-2010-10-311589

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  56 in total

Review 1.  Cellular and molecular mechanisms of neural repair after stroke: making waves.

Authors:  S Thomas Carmichael
Journal:  Ann Neurol       Date:  2006-05       Impact factor: 10.422

Review 2.  A role for axon guidance receptors and ligands in blood vessel development and tumor angiogenesis.

Authors:  Michael Klagsbrun; Anne Eichmann
Journal:  Cytokine Growth Factor Rev       Date:  2005 Aug-Oct       Impact factor: 7.638

3.  Effects of hyperoxia on microvascular cells in vitro.

Authors:  P A D'Amore; E Sweet
Journal:  In Vitro Cell Dev Biol       Date:  1987-02

4.  L-arginine transport in retinas from streptozotocin diabetic rats: correlation with the level of IL-1 beta and NO synthase activity.

Authors:  A Carmo; J G Cunha-Vaz; A P Carvalho; M C Lopes
Journal:  Vision Res       Date:  1999-11       Impact factor: 1.886

5.  Diabetes, diabetic angiopathy, and growth hormone.

Authors:  K Lundbaek; N J Christensen; V A Jensen; K Johansen; T S Olsen; A P Hansen; H Orskov; R Osterby
Journal:  Lancet       Date:  1970-07-18       Impact factor: 79.321

Review 6.  Proliferative retinopathies: angiogenesis that blinds.

Authors:  Przemyslaw Sapieha; David Hamel; Zhuo Shao; Jose Carlos Rivera; Karine Zaniolo; Jean Sébastien Joyal; Sylvain Chemtob
Journal:  Int J Biochem Cell Biol       Date:  2009-10-15       Impact factor: 5.085

7.  Differential expression of angioregulatory factors in normal and CNV-derived human retinal pigment epithelium.

Authors:  Gottfried Martin; Günther Schlunck; Lutz L Hansen; Hansjürgen T Agostini
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-01-14       Impact factor: 3.117

8.  Semaphorin III is needed for normal patterning and growth of nerves, bones and heart.

Authors:  O Behar; J A Golden; H Mashimo; F J Schoen; M C Fishman
Journal:  Nature       Date:  1996-10-10       Impact factor: 49.962

Review 9.  Pathogenesis of retinopathy of prematurity.

Authors:  Lois E H Smith
Journal:  Growth Horm IGF Res       Date:  2004-06       Impact factor: 2.372

10.  Semaphorin-3A and semaphorin-3F work together to repel endothelial cells and to inhibit their survival by induction of apoptosis.

Authors:  Noga Guttmann-Raviv; Niva Shraga-Heled; Asya Varshavsky; Cinthya Guimaraes-Sternberg; Ofra Kessler; Gera Neufeld
Journal:  J Biol Chem       Date:  2007-06-14       Impact factor: 5.157

View more
  77 in total

1.  Collapsin response mediator proteins (CRMPs) are a new class of microtubule-associated protein (MAP) that selectively interacts with assembled microtubules via a taxol-sensitive binding interaction.

Authors:  Pao-Chun Lin; Perry M Chan; Christine Hall; Ed Manser
Journal:  J Biol Chem       Date:  2011-09-27       Impact factor: 5.157

2.  Ferrochelatase regulates retinal neovascularization.

Authors:  Sardar Pasha Sheik Pran Babu; Darcy White; Timothy W Corson
Journal:  FASEB J       Date:  2020-07-27       Impact factor: 5.191

3.  Nogo-A targeted therapy promotes vascular repair and functional recovery following stroke.

Authors:  Ruslan Rust; Lisa Grönnert; Christina Gantner; Alinda Enzler; Geertje Mulders; Rebecca Z Weber; Arthur Siewert; Yanuar D P Limasale; Andrea Meinhardt; Michael A Maurer; Andrea M Sartori; Anna-Sophie Hofer; Carsten Werner; Martin E Schwab
Journal:  Proc Natl Acad Sci U S A       Date:  2019-06-24       Impact factor: 11.205

Review 4.  Plexin structures are coming: opportunities for multilevel investigations of semaphorin guidance receptors, their cell signaling mechanisms, and functions.

Authors:  Prasanta K Hota; Matthias Buck
Journal:  Cell Mol Life Sci       Date:  2012-06-29       Impact factor: 9.261

5.  Gleevec/imatinib, an ABL2 kinase inhibitor, protects tumor and endothelial cells from semaphorin-induced cytoskeleton collapse and loss of cell motility.

Authors:  Vera Procaccia; Hironao Nakayama; Akio Shimizu; Michael Klagsbrun
Journal:  Biochem Biophys Res Commun       Date:  2014-04-20       Impact factor: 3.575

6.  The potential of anti-VEGF (Vasotide) by eye drops to treat proliferative retinopathies.

Authors:  Jennifer L Wilkinson-Berka; Devy Deliyanti
Journal:  Ann Transl Med       Date:  2016-10

7.  Secretion of Down Syndrome Critical Region 1 Isoform 4 in Ischemic Retinal Ganglion Cells Displays Anti-Angiogenic Properties Via NFATc1-Dependent Pathway.

Authors:  Yue Xu; Boyu Yang; Yaguang Hu; Lin Lu; Xi Lu; Jiawei Wang; Qinmeng Shu; Qiaochu Cheng; Shanshan Yu; Fan Xu; Jingjing Huang; Xiaoling Liang
Journal:  Mol Neurobiol       Date:  2016-10-12       Impact factor: 5.590

8.  Truncated netrin-1 contributes to pathological vascular permeability in diabetic retinopathy.

Authors:  Khalil Miloudi; François Binet; Ariel Wilson; Agustin Cerani; Malika Oubaha; Catherine Menard; Sullivan Henriques; Gaelle Mawambo; Agnieszka Dejda; Phuong Trang Nguyen; Flavio A Rezende; Steve Bourgault; Timothy E Kennedy; Przemyslaw Sapieha
Journal:  J Clin Invest       Date:  2016-07-11       Impact factor: 14.808

Review 9.  Diabetic retinopathy: current understanding, mechanisms, and treatment strategies.

Authors:  Elia J Duh; Jennifer K Sun; Alan W Stitt
Journal:  JCI Insight       Date:  2017-07-20

10.  Nutrition, insulin-like growth factor-1 and retinopathy of prematurity.

Authors:  Anna-Lena Hård; Lois E Smith; Ann Hellström
Journal:  Semin Fetal Neonatal Med       Date:  2013-02-18       Impact factor: 3.926

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.